SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
G1 Therapeutics, Inc. (GTHX) , 前瞻盈利收益率 142.86%.
本页证实的标准:
- VALUE (10/100, 未通过) — 分析师共识目标价暗示当前价格存在下行风险 ($4.50, 37.2%).
- 前瞻市盈率 0.7
- 分析师共识目标价 $4.50 (-37.2% 下行风险) — 分析师认为当前价格水平存在明显下行风险。
SharesGrow 综合评分： 33/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✗
价值
10/100
Price-to-Earnings & upside
Proven by this page
✗
健康
33/100
Debt-to-Equity & liquidity
→ Health
估值概览 — GTHX
估值倍数
P/E (TTM)0.0
前瞻 P/E0.7
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率4.49
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.93
前瞻 EPS（预估）$10.18
每股账面价值$0.00
每股营收$1.59
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
Forward Earnings Yield142.86%
股息收益率0.00%
分析师目标价$4.50 (-37.2%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2014 |
$-5.85 |
$1.04M |
$-7.18M |
-688.6% |
| 2015 |
$-0.99 |
$522K |
$-20.26M |
-3881.8% |
| 2016 |
$-1.48 |
$0.00 |
$-30.29M |
- |
| 2017 |
$-3.30 |
$0.00 |
$-60.12M |
- |
| 2018 |
$-2.56 |
$0.00 |
$-85.29M |
- |
| 2019 |
$-3.26 |
$0.00 |
$-122.09M |
- |
| 2020 |
$-2.62 |
$45.29M |
$-99.25M |
-219.2% |
| 2021 |
$-3.54 |
$31.48M |
$-148.35M |
-471.3% |
| 2022 |
$-3.38 |
$51.3M |
$-147.56M |
-287.6% |
| 2023 |
$-0.93 |
$82.51M |
$-47.97M |
-58.1% |
